Survival Outcomes by Race Following Surgical Treatment for Upper Tract Urothelial Carcinoma.

Autor: Zappia J; Department of Urology, Indiana University, Indianapolis, IN. Electronic address: jzappia@iu.edu., Yong C; Department of Urology, Indiana University, Indianapolis, IN., Slaven J; Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, IN., Wu Z; Department of Urology, Changhai Hospital, Naval Medical University, SH, China., Wang L; Department of Urology, Changhai Hospital, Naval Medical University, SH, China., Djaladat H; Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA., Wood E; Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA., Ghoreifi A; Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA., Abdollah F; Henry Ford Hospital, Vattikuti Urology Institute, Detroit, MI., Davis M; Henry Ford Hospital, Vattikuti Urology Institute, Detroit, MI., Stephens A; Henry Ford Hospital, Vattikuti Urology Institute, Detroit, MI., Simone G; Department of Urology, IRCCS 'Regina Elena' National Cancer Institute, Rome, Italy., Tuderti G; Department of Urology, IRCCS 'Regina Elena' National Cancer Institute, Rome, Italy., Gonzalgo ML; Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL., Mendiola DF; Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL., Derweesh IH; Department of Urology, UC San Diego School of Medicine, La Jolla, CA., Dhanji S; Department of Urology, UC San Diego School of Medicine, La Jolla, CA., Hakimi K; Department of Urology, UC San Diego School of Medicine, La Jolla, CA., Margulis V; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX., Taylor J; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX., Ferro M; Division of Urology, European Institute of Oncology (IEO)-IRCCS, Milan, Italy., Tozzi M; Division of Urology, European Institute of Oncology (IEO)-IRCCS, Milan, Italy., Autorino R; Division of Urology, Rush University, Chicago, IL., Pandolfo SD; Division of Urology, VCU Health, Richmond, VA., Mehrazin R; Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY., Eilender B; Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY., Porpiglia F; Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Turin, Italy., Checcucci E; Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Turin, Italy., Sundaram CP; Department of Urology, Indiana University, Indianapolis, IN.
Jazyk: angličtina
Zdroj: Clinical genitourinary cancer [Clin Genitourin Cancer] 2024 Sep 06; Vol. 22 (6), pp. 102220. Date of Electronic Publication: 2024 Sep 06.
DOI: 10.1016/j.clgc.2024.102220
Abstrakt: Objective: Discrepancies in survival outcomes of various genitourinary tract malignancies have been documented across different racial and ethnic groups. Here we sought to examine long-term survival outcomes of patients with upper tract urothelial carcinoma (UTUC) following radical nephroureterectomy (RNU) when stratified by race.
Methods: A multicenter retrospective analysis using the ROBUUST (ROBotic surgery for Upper tract Urothelial cancer Study) registry identified patients undergoing RNU for UTUC between 2015 and 2022 at 12 centers across the United States, Europe, and Asia. Patients were stratified by race (white, black, Hispanic, and Asian) and primary outcomes of interest-including recurrence-free survival (RFS), metastasis free survival (MFS) and overall survival (OS) - were assessed using univariate analysis, multivariate Cox regression modeling, and Kaplan-Meier analysis.
Results: 1446 patients (white n = 652, black n = 70, Hispanic n = 87, and Asian n = 637) who underwent RNU for treatment of the UTUC were included in our analysis. Cox regression modeling demonstrated pathologic nodal staging to be a significant predictor of RFS (HR 2.25; P = .0010), MFS (HR 2.50; P = .0028), and OS (HR 5.11; P < .0001). When using whites as the reference group, there were no significant differences in RFS, MFS, or OS across racial groups.
Conclusions: Unlike other genitourinary tract malignancies, our study failed to demonstrate a survival disadvantage among minority racial groups with UTUC who underwent RNU. Furthermore, a significant difference in RFS, MFS, and OS was not identified across whites, blacks, Asians, or Hispanics with UTUC who underwent RNU.
Competing Interests: Disclosure The authors have stated that they have no conflicts of interest.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: